KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Deferred Taxes (2016 - 2025)

Regeneron Pharmaceuticals has reported Deferred Taxes over the past 13 years, most recently at $232.5 million for Q4 2025.

  • Quarterly results put Deferred Taxes at $232.5 million for Q4 2025, down 17.02% from a year ago — trailing twelve months through Dec 2025 was $785.4 million (up 3.71% YoY), and the annual figure for FY2025 was $785.4 million, up 3.71%.
  • Deferred Taxes for Q4 2025 was $232.5 million at Regeneron Pharmaceuticals, down from $278.6 million in the prior quarter.
  • Over the last five years, Deferred Taxes for REGN hit a ceiling of $286.3 million in Q4 2023 and a floor of -$41.7 million in Q2 2021.
  • Median Deferred Taxes over the past 5 years was $179.5 million (2024), compared with a mean of $163.7 million.
  • Biggest five-year swings in Deferred Taxes: crashed 7100.0% in 2021 and later skyrocketed 2327.72% in 2022.
  • Regeneron Pharmaceuticals' Deferred Taxes stood at $205.9 million in 2021, then surged by 35.84% to $279.7 million in 2022, then grew by 2.36% to $286.3 million in 2023, then decreased by 2.13% to $280.2 million in 2024, then fell by 17.02% to $232.5 million in 2025.
  • The last three reported values for Deferred Taxes were $232.5 million (Q4 2025), $278.6 million (Q3 2025), and $135.2 million (Q2 2025) per Business Quant data.